Flexeril (cyclobenzaprine) is not a controlled substance. The Drug Enforcement Administration explicitly states that cyclobenzaprine is not controlled under the Controlled Substances Act, meaning it has no DEA schedule designation. Your doctor can prescribe it on a standard prescription without the special restrictions that apply to drugs like opioids or benzodiazepines.
That said, “not controlled” doesn’t mean “no risks.” Cyclobenzaprine acts on the central nervous system, and there are real reasons people search this question. Here’s what you should know.
Why Flexeril Isn’t Scheduled
The DEA assigns drugs to schedules (I through V) based on their potential for abuse and physical dependence. Cyclobenzaprine doesn’t produce the kind of euphoria or reinforcing “high” that typically drives addiction. It works in the brainstem to calm overactive muscle signals, blocking certain serotonin receptors rather than activating the reward pathways that opioids and benzodiazepines target. Its chemical structure is actually closer to older antidepressants (tricyclics) than to any classic drug of abuse.
This matters practically. Because Flexeril isn’t scheduled, pharmacies can transfer prescriptions between locations, refills don’t require a new written prescription each time (depending on state rules), and there’s no monitoring through prescription drug monitoring programs the way there would be for a Schedule IV muscle relaxant like carisoprodol (Soma).
How It Compares to Soma and Other Muscle Relaxants
Not all muscle relaxants share the same legal status. Carisoprodol (Soma) became a Schedule IV controlled substance in 2012 after mounting evidence of widespread abuse and diversion. The key difference is pharmacological: carisoprodol breaks down in the body into meprobamate, a compound that acts similarly to barbiturates and directly enhances the brain’s primary calming chemical system (GABA). That mechanism produces sedation and euphoria in a way cyclobenzaprine does not. DEA data showed that drug-related seizures from carisoprodol topped 5,000 in 2010, surpassing even some well-known controlled substances like lorazepam and methylphenidate.
Cyclobenzaprine works through an entirely different pathway. It reduces muscle spasm activity by dampening signals in the brainstem and spinal cord without directly affecting the neuromuscular junction or triggering the GABA-related reward response. This is the core reason the DEA has never moved to schedule it.
Misuse Still Happens
The absence of a controlled substance label doesn’t mean cyclobenzaprine is free from misuse. Some people take it in higher-than-prescribed doses for its sedative effects, and it does show up in overdose reports. An FDA review of postmarketing safety data found that the most common serious adverse events included intentional and accidental overdose, loss of consciousness, seizures, dangerously low blood pressure, hallucinations, and coma. Most overdose cases involved cyclobenzaprine taken alongside other substances.
Mixing Flexeril with alcohol, benzodiazepines, or opioids significantly increases the risk of dangerous sedation. Because cyclobenzaprine is structurally related to tricyclic antidepressants, combining it with other drugs that raise serotonin levels can also trigger serotonin syndrome, a potentially life-threatening condition marked by agitation, rapid heart rate, high body temperature, and muscle rigidity.
What This Means for Your Prescription
If your doctor prescribes Flexeril for muscle spasms, you won’t face the same pharmacy hurdles as you would with a controlled substance. There’s no limit on call-in prescriptions, no requirement for a physical paper prescription in most states, and no automatic flag in a prescription monitoring database. Insurance companies and pharmacies treat it like any other non-controlled medication.
However, cyclobenzaprine is typically intended for short-term use, generally two to three weeks. It causes drowsiness in a large percentage of people who take it, and that sedation can be significant enough to impair driving. Dry mouth, dizziness, and fatigue are also common. Stopping it abruptly after extended use can occasionally cause mild withdrawal-like symptoms such as nausea and headache, even though formal physical dependence is uncommon.
Some states or individual healthcare systems may apply their own prescribing restrictions that go beyond federal law, so local rules can occasionally make the refill process slightly more involved than for a typical non-controlled drug. If you’re uncertain, your pharmacist can clarify what applies in your area.